BECTON DICKINSON & CO's ticker is BDX and the CUSIP is 075887109. A total of 1,539 filers reported holding BECTON DICKINSON & CO in Q2 2024. The put-call ratio across all filers is 1.11 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GATEWAY INVESTMENT ADVISERS LLC | 2,327 | $543,937 | 0.01% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 131,282 | $30,681,916 | 0.01% |
| Douglas Lane & Associates, LLC | 1,745 | $407,883 | 0.01% |
| Walleye Trading LLC | 11,700 | $2,734,407 | 0.01% |
| PARK AVENUE SECURITIES LLC | 2,151 | $503 | 0.01% |
| Citadel Advisors | 126,400 | $29,540,944 | 0.01% |
| AE Wealth Management LLC | 2,482 | $580,180 | 0.01% |
| Fortitude Family Office, LLC | 49 | $11,452 | 0.01% |
| Continuum Advisory, LLC | 192 | $44,872 | 0.01% |
| Connor, Clark & Lunn Investment Management Ltd. | 5,773 | $1,349,208 | 0.01% |
| Aspire Private Capital, LLC | 102 | $23,838 | 0.01% |
| WOLVERINE TRADING, LLC | 22,600 | $5,281,846 | 0.01% |
| CX Institutional | 514 | $120,130 | 0.01% |
| JNBA Financial Advisors | 246 | $57,493 | 0.01% |
| Central Pacific Bank - Trust Division | 200 | $46,742 | 0.01% |
| REDMONT WEALTH ADVISORS LLC | 15 | $3,506 | 0.01% |
| Zions Bancorporation, N.A. | 344 | $80,396 | 0.01% |
| Walleye Capital LLC | 13,700 | $3,201,827 | 0.01% |
| TUCKER ASSET MANAGEMENT LLC | 93 | $21,735 | 0.01% |
| FINANCIAL COUNSELORS INC | 1,272 | $297,279 | 0.01% |
About BECTON DICKINSON & CO
Becton Dickinson & Co. (BD) is a global medical technology company that specializes in the development, manufacturing, and sale of medical devices, instrument systems, and reagents. The company is headquartered in Franklin Lakes, New Jersey, and has operations in over 50 countries worldwide.
BD's products are used in a variety of healthcare settings, including hospitals, clinics, laboratories, and blood banks. The company's portfolio includes products for medication management, infection prevention, diagnostic testing, and surgical procedures.
BD has a strong track record of innovation, with a focus on developing products that improve patient outcomes and reduce healthcare costs. The company invests heavily in research and development, with over 2,000 patents and patent applications worldwide.
In recent years, BD has made several strategic acquisitions to expand its product portfolio and geographic reach. In 2017, the company acquired C.R. Bard, a leading provider of medical devices for vascular, urology, and oncology applications. This acquisition has strengthened BD's position in the global medical technology market and is expected to drive long-term growth.
BD has a strong financial position, with a market capitalization of over $70 billion and a dividend yield of 1.3%. The company has a solid track record of revenue growth and profitability, with a five-year revenue growth rate of 6.5% and a net profit margin of 9.5%.
Overall, BD is a well-established and innovative company with a strong position in the global medical technology market. With a focus on improving patient outcomes and reducing healthcare costs, the company is well-positioned for long-term growth and success.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BECTON DICKINSON & CO's shareholders in Q2 2024. To view BECTON DICKINSON & CO's shareholder history, click here.